accounting for T-cell death in vivo are not known, HIV-1 infection profoundly influences the T-cell repertoire, both in CD4 þ and in CD8 þ T cells in vivo. 3 Animal models such as the infection of macaques by simian immunodeficiency virus (SIV) may be important for the elucidation of the exact molecular mechanisms of the apoptotic pathways participating in the pathogenesis of AIDS.
Importantly, HIV-1 provokes a neuropathological response involving all cell types in the brain. The incidence of the socalled HIV-1-associated dementia (HAD) is increasing, and its pathogenesis is likely to be complex, involving multiple direct and indirect apoptosis-inducing mechanisms culminating in neurodegeneration. [11] [12] [13] Soluble viral products such as gp120 and Tat as well as inflammatory responses play a major role in HAD. 12 Moreover, direct mechanisms leading to the formation of synctia may contribute to HAD. The apoptotic response of synctia is likely to involve the activation of p53, 4, 12 illustrating how host cell-intrinsic factors can contribute to viral pathogenesis.
Human T-cell leukemia virus type 1 (HTLV-1) is responsible for adult T-cell leukemia/lymphoma, as well as progressive demyelinating neurodegenerative disease termed HTLVassociated myelopathy/tropica spastic paraparesis. HTLV-1 encodes the viral oncogene Tax, which can inhibit apoptosis through the activation of the NF-kB pathway.
14 In addition, HTLV-1 encodes for a protein, p13II, which can sensitize for apoptosis induction, presumably through a direct effect on the mitochondrial inner membrane. 15 How and to which extent p13/II contributes to the HTLV-1-mediated disease states remains on open conundrum. Antiretroviral agents used for the treatment of AIDS can modulate host cell apoptosis, even in the absence of retroviruses. 16, 17 Thus, HIV-1 protease inhibitors can both inhibit and induce apoptosis, depending on the dose and on the cell type investigated. 16 It may thus be speculated that such drugs may become useful in clinical applications in which apoptosis modulation is a therapeutic goal. 17 We do hope that the readers of Cell Death and Differentiation will appreciate the present compendium of articles on retroviral and antiretroviral modulation of cell death pathways. May the ideas shared by the authors stimulate further debate and experimentation. It appears reasonable to anticipate that a detailed comprehension of cell death modulation by retroviruses will open new therapeutic avenues that may reduce viral reproduction, boost antiretroviral immune responses or, alternatively, dampen deleterious host cell loss, for instance in the central nervous system.
